A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Any another primary malignancy within the 3 years prior to enrollment

Known, active primary central nervous system (CNS) malignancy

History of prior adoptive cell and gene therapy, allogeneic stem cell transplant or solid organ transplantation.

History of clinically significant cardiac disease within the 6 months prior to enrollment or heart failure at any time prior to enrollment.